Autism drug is moved into late-stage clinical trials

09/9/2010 | American City Business Journals

Seaside Therapeutics will proceed with late-stage trials of a drug treatment for fragile X syndrome and autism spectrum disorder. The move comes after a second Phase II study showed that the treatment significantly improved the symptoms of patients ages 6 to 17 with autism spectrum disorder.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Education

Job Title Company Location
School District of Philadelphia - Director, Observation and Feedback Coaches Program
School District of Philadelphia
Philadelphia, PA
Research Scientist
NWEA
Portland, OR
Opportunities for Former Teachers and Administrators with PLC Experience
Learning Sciences International
Nationwide, SL_Nationwide
Instructional Designer, ESL
Imagine Learning, Inc.
Provo, UT
Account Executive, National Accounts
NWEA
Nationwide, SL_Nationwide